2.76
Schlusskurs vom Vortag:
$2.81
Offen:
$2.72
24-Stunden-Volumen:
156.58K
Relative Volume:
0.32
Marktkapitalisierung:
$177.94M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-45.08M
KGV:
-3.7808
EPS:
-0.73
Netto-Cashflow:
$-33.68M
1W Leistung:
-1.43%
1M Leistung:
-10.10%
6M Leistung:
-24.80%
1J Leistung:
+112.31%
Galectin Therapeutics Inc Stock (GALT) Company Profile
Firmenname
Galectin Therapeutics Inc
Sektor
Branche
Telefon
678-620-3186
Adresse
4960 PEACHTREE INDUSTRIAL BOULEVARD, NORCROSS, GA
Compare GALT vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
|
GALT
Galectin Therapeutics Inc
|
2.76 | 181.17M | 0 | -45.08M | -33.68M | -0.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
491.47 | 117.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
803.17 | 82.85B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
821.96 | 51.58B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.40 | 40.75B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.07 | 38.33B | 4.98B | 69.60M | 525.67M | 0.5198 |
Galectin Therapeutics Inc Stock (GALT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-17 | Fortgesetzt | H.C. Wainwright | Buy |
| 2020-08-13 | Bestätigt | H.C. Wainwright | Buy |
| 2019-02-13 | Eingeleitet | B. Riley FBR | Buy |
| 2017-12-07 | Bestätigt | H.C. Wainwright | Buy |
| 2017-11-28 | Bestätigt | H.C. Wainwright | Buy |
| 2017-10-19 | Eingeleitet | ROTH Capital | Buy |
| 2017-03-30 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2016-10-03 | Herabstufung | FBR & Co. | Outperform → Mkt Perform |
| 2016-09-29 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2016-09-28 | Herabstufung | ROTH Capital | Buy → Sell |
| 2016-03-28 | Fortgesetzt | H.C. Wainwright | Buy |
| 2015-09-21 | Eingeleitet | H.C. Wainwright | Buy |
| 2014-08-01 | Herabstufung | Aegis Capital | Buy → Hold |
| 2014-07-30 | Bestätigt | MLV & Co | Buy |
| 2014-07-29 | Bestätigt | MLV & Co | Buy |
| 2014-04-02 | Bestätigt | MLV & Co | Buy |
| 2014-02-10 | Bestätigt | Aegis Capital | Buy |
| 2014-01-09 | Bestätigt | Aegis Capital | Buy |
| 2013-12-03 | Eingeleitet | MLV & Co | Buy |
| 2013-08-19 | Bestätigt | Aegis Capital | Buy |
Alle ansehen
Galectin Therapeutics Inc Aktie (GALT) Neueste Nachrichten
Will Galectin Therapeutics Inc. stock deliver long term returns2025 Volatility Report & Safe Capital Allocation Plans - mfd.ru
What’s the outlook for Galectin Therapeutics Inc.’s sectorMarket Growth Review & Fast Exit/Entry Strategy Plans - mfd.ru
Buy Signal: Whats the outlook for Galectin Therapeutics Incs sectorPortfolio Return Report & AI Based Trade Execution Alerts - baoquankhu1.vn
Short Covering: How is MLKN managing supply chain issues2025 Trading Recap & Fast Moving Stock Watchlists - baoquankhu1.vn
Aug Chart Watch: Is Galectin Therapeutics Inc gaining market shareJuly 2025 Recap & Accurate Intraday Trade Tips - baoquankhu1.vn
Galectin Therapeutics Inc.'s (NASDAQ:GALT) market cap dropped US$39m last week; Individual investors bore the brunt - simplywall.st
Can Galectin Therapeutics Inc expand into new marketsJobs Report & Real-Time Volume Analysis - baoquankhu1.vn
Meme Stocks: Will Galectin Therapeutics Inc outperform its industry peersMarket Activity Report & Expert Approved Momentum Ideas - baoquankhu1.vn
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Galectin Therapeutics Inc.GALT - yourwyominglink.com
Galectin Therapeutics Inc.'s (NASDAQ:GALT) top owners are retail investors with 55% stake, while 20% is held by insiders - Yahoo Finance
Galectin Therapeutics Approves Retention Bonuses for Key Executives - The Globe and Mail
Moving Averages: What is the Moat Score of WVVIPBuy Signal & Fast Entry and Exit Trade Plans - baoquankhu1.vn
Analysis Recap: Can Galectin Therapeutics Inc be the next market leaderTrade Entry Report & Smart Investment Allocation Insights - baoquankhu1.vn
Portfolio Update: Is DNAWS a potential multi baggerEarnings Beat & Free Real-Time Volume Trigger Notifications - baoquankhu1.vn
Galectin Therapeutics Inc. (NASDAQ:GALT) Short Interest Update - MarketBeat
Galectin Therapeutics Under Investigation, Stock Plummets 28.9% - Intellectia AI
Is Galectin Therapeutics Inc. gaining market shareJuly 2025 Analyst Calls & Safe Entry Point Identification - baoquankhu1.vn
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Galectin Therapeutics Inc. (GALT) And Encourages Shareholders to Reach Out - ACCESS Newswire
Insider Buy: Can BROG navigate macro headwindsWeekly Investment Summary & Real-Time Volume Trigger Notifications - baoquankhu1.vn
Growth Review: Is Galectin Therapeutics Inc stock affected by interest rate hikesQuarterly Earnings Report & Daily Growth Stock Investment Tips - Bộ Nội Vụ
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Galectin Therapeutics Inc. (GALT) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
Galectin Therapeutics Inc. (GALT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - accessnewswire.com
Galectin Therapeutics director Marc Rubin resigns from board By Investing.com - Investing.com India
Galectin Therapeutics announces board resignation of Marc Rubin - TipRanks
Galectin Therapeutics director Marc Rubin resigns from board - Investing.com
Bronstein, Gewirtz & Grossman, LLC Encourages Galectin Therapeutics Inc. (GALT) Shareholders to Inquire about Securities Investigation - accessnewswire.com
Will Galectin Therapeutics Inc. stock continue dividend increasesJuly 2025 Closing Moves & Detailed Earnings Play Strategies - ulpravda.ru
Bronstein, Gewirtz & Grossman, LLC Is Investigating Galectin Therapeutics Inc. (GALT) And Encourages Investors to Connect - ACCESS Newswire
Galectin Therapeutics Inc.'s (NASDAQ:GALT) Last Week's 23% Decline Must Have Disappointed Individual Investors Who Have a Significant Stake - 富途牛牛
Can Galectin Therapeutics Inc. (PHPN) stock sustain institutional flowsJuly 2025 Drop Watch & AI Enhanced Execution Alerts - Улправда
Is Galectin Therapeutics Inc. (PHPN) stock a safe buy pre earningsJuly 2025 Spike Watch & Fast Gain Swing Trade Alerts - Улправда
Will Galectin Therapeutics Inc. stock benefit from automationJuly 2025 Trade Ideas & High Accuracy Investment Entry Signals - Улправда
Fraud Investigation Opened: Levi & Korsinsky Investigates Galectin Therapeutics Inc. (GALT) on Behalf of Shareholders - ACCESS Newswire
Is Galectin Therapeutics Inc. stock resilient to inflationJuly 2025 Review & Precise Swing Trade Entry Alerts - Улправда
How buybacks impact Galectin Therapeutics Inc. stock value2025 Momentum Check & Consistent Return Strategy Ideas - Улправда
MACD Signal: Will Galectin Therapeutics Inc. stock benefit from automation2025 Technical Overview & Community Consensus Trade Alerts - Улправда
Is Galectin Therapeutics Inc. stock attractive for income investors2025 Growth vs Value & High Win Rate Trade Tips - Улправда
Institution Moves: Will Galectin Therapeutics Inc. (PHPN) stock beat Nasdaq index returnsJuly 2025 Earnings & Safe Investment Capital Preservation Plans - ulpravda.ru
Market Trends: Will Galectin Therapeutics Inc PHPN stock beat Nasdaq index returnsJuly 2025 Retail & Real-Time Volume Analysis Alerts - Bộ Nội Vụ
Fraud Investigation: Levi & Korsinsky Investigates Galectin Therapeutics Inc. (GALT) on Behalf of Shareholders - ACCESS Newswire
GALT Investors Have Opportunity to Join Galectin Therapeutics Inc. Fraud Investigation with the Schall Law Firm - GlobeNewswire
Galectin Therapeutics CFO sells $233k in shares By Investing.com - Investing.com Nigeria
Galectin Therapeutics CFO sells $233k in shares - Investing.com
Insider Sell: Jack Callicutt Sells 60,000 Shares of Galectin The - GuruFocus
Khurram Jamil Sells 21,446 Shares of Galectin Therapeutics (NASDAQ:GALT) Stock - MarketBeat
Galectin Therapeutics (NASDAQ:GALT) CFO Sells $58,438.80 in Stock - MarketBeat
Insider Selling: Galectin Therapeutics (NASDAQ:GALT) CEO Sells 18,571 Shares of Stock - MarketBeat
Joel Lewis Sells 27,731 Shares of Galectin Therapeutics (NASDAQ:GALT) Stock - MarketBeat
Galectin Therapeutics (NASDAQ:GALT) Insider Khurram Jamil Sells 13,055 Shares - MarketBeat
Insider Selling: Galectin Therapeutics (NASDAQ:GALT) CFO Sells 20,354 Shares of Stock - MarketBeat
Galectin Therapeutics Faces Securities Fraud Investigation as Stock Plummets 28.9% - Intellectia AI
Finanzdaten der Galectin Therapeutics Inc-Aktie (GALT)
Umsatz
Nettogewinn
Free Cashflow
ENV
Galectin Therapeutics Inc-Aktie (GALT) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| LEWIS JOEL | President and CEO |
Jan 02 '26 |
Option Exercise |
0.00 |
84,000 |
0 |
916,592 |
| LEWIS JOEL | President and CEO |
Jan 06 '26 |
Sale |
3.58 |
37,698 |
134,853 |
832,592 |
| LEWIS JOEL | President and CEO |
Jan 05 '26 |
Sale |
3.91 |
27,731 |
108,342 |
870,290 |
| LEWIS JOEL | President and CEO |
Jan 02 '26 |
Sale |
4.20 |
18,571 |
77,939 |
898,021 |
| CALLICUTT JACK W | Chief Financial Officer |
Jan 02 '26 |
Option Exercise |
0.00 |
60,000 |
0 |
67,614 |
| CALLICUTT JACK W | Chief Financial Officer |
Jan 05 '26 |
Sale |
3.90 |
25,732 |
100,298 |
27,968 |
| CALLICUTT JACK W | Chief Financial Officer |
Jan 06 '26 |
Sale |
3.67 |
20,354 |
74,695 |
7,614 |
| CALLICUTT JACK W | Chief Financial Officer |
Jan 02 '26 |
Sale |
4.20 |
13,914 |
58,394 |
53,700 |
| Jamil Khurram | Chief Medical Officer |
Jan 02 '26 |
Option Exercise |
0.00 |
60,000 |
0 |
60,000 |
| Jamil Khurram | Chief Medical Officer |
Jan 05 '26 |
Sale |
3.90 |
25,499 |
99,408 |
21,446 |
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):